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AN ANALYSIS OF THE EFFICACY OF CALCITONIN GENE-RELATED 
PEPTIDE INHIBITORS ON THE TREATMENT OF MIGRAINE IN ADULTS 
KRISTIN NZERUE 
ABSTRACT 
 The CGRP monoclonal antibodies are the first class of medication developed 
specifically for migraine prevention, in contrast to previous preventative medications, 
that were in the anti-hypertensive, anti-epileptic and anti-depressant class.  There are two 
notable divisions within the CGRP inhibitor class: the CGRP monoclonal antibodies 
(CGRP mAbs), and the small molecule CGRP antagonists (gepants). This thesis conducts 
a retrospective analysis of notable clinical trials such as the ACHIEVE I, ACHIEVE II, 
LIBERTY, ARISE, STRIVE, PREEMPT, and COMPEL studies to determine the 
efficacy of CGRP inhibitors. In ACHIEVE I, 38.6% of participants in the 50 mg 
ubrogepant group experienced pain freedom 2 hours post dose (p=0.002) and in 
ACHIEVE II trial in the 50 mg ubrogepant group, 21.8% reported pain freedom 2 hours. 
In participants that received Rimegepant at a 75mg dose, 21%of participants reported 
more freedom from pain at 2 hours than placebo (p<0.0001).40  In another study, 
participants received placebo, 50 mg and 100 mg of sumatriptan.43 Results of the study 
showed that more than half of participants, 57%, in the 100 mg Sumatriptan group and 
exactly half of participants in the 50 mg group had pain relief at 2 hours post-dose.43 In 
the LIBERTY trial, at 12 weeks, 30% of  individuals that received erenumab  reported a 
fifty percent or more reduction in the monthly number of migraine days than individuals 
in the placebo group (p=0.002).45 In the STRIVE trial, the average number of migraine 
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days experienced by the participant at  baseline was 8.3, and was assessed by the 4th 
month through the 6th month. This baseline decreased to 5.1 days (a 3.2 difference) in the 
participants that received an injection of 70 mg of erenumab (p<0.001). 46 The 
participants that received an injection of 140 mg erenumab, decreased from the baseline 
to 4.6 days of migraine (a 3.7 difference) (p<0.001) . 46 Participants that received placebo 
reported the least change from baseline, only a 1.8 day change (p<0.001).46 In the ARISE 
Trial patients receiving erenumab experienced a change of 2.9 monthly migraine days, a 
1.1 increase from the reported change of 1.8 days reported by study participants for the 
monthly migraine days in the placebo group (p<0.001).47 The PREEMPT1 trial did not 
meet statistical significance for their primary endpoint or study measure, which was to 
assess for a mean change in monthly mean headache episode frequency between baseline 
and week 24 of the trial (p=0.344)48. Participants in the PREEMPT2 trial experienced a 
reduction by 9 days when compared to placebo for the primary end point, frequency of 
headache days per 28 days relative to baseline (p<0.001)49. In the COMPEL study, 
participants experienced -10.7 day reduction in headache days by 108 weeks 
(p<0.0001).50 There are several advantages to CGRP mAbs. Patients are more likely to 
adhere to CGRP mAbs medication and tolerate this medication than other medication 
options17, CGRP mAbs do not give rise to toxicity in the liver because these medications 
do not interact with the liver17, and CGRP mAbs have a long duration in the human body 
as they have a half-life of 20 to 30 days which provides patients with the opportunity to 
not take the medication as frequently. 51 Another reason why CGRP mAbs are 
advantageous compared to traditional treatment options is that they have a strong affinity 
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and specificity for the CGRP receptor or CGRP molecule. This high specificity prevents 
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 The 2nd leading condition that contributes to years of life lived with 
disability worldwide is migraine.1 In 2016, it was estimated that there were 1 billion 
people living with migraine disorder.1 This disorder effects both sexes and effects people 
of all ages, and presents a tremendous burden to women aged 15-49 years.1 It is 
important to study and understand migraine disorder as it effects individuals of various 
racial and socioeconomic backgrounds. To evaluate the current literature concerning 
migraines, this thesis will examine the existing literature such as the theories of migraine 
pathophysiology, and conventional acute and preventative migraine treatments. 
Furthermore, data from clinical trials of the CGRP mAbs, CGRP receptor antagonists 
(gepants), OnabotulinumtoxinA (Botox), and sumatriptan will be analyzed and compared. 
Finally, the methodology between these trials will be discussed. For acute treatment, 
rimegepant and ubrogepant will be compared to sumatriptan, which is prescribed more 
than any other triptan for acute migraine treatment in the United States. Additionally, the 
efficacy of erenumab will be compared to Botox for the prevention of chronic migraine, 
as erenumab is currently the most commonly prescribed CGRP mAbs, and at the time of 
this thesis, the CGRP mAbs and Botox are the only FDA approved preventative therapies 
for use in chronic migraine. In conducting this study, the aim is to determine the efficacy 
of the CGRP class of medications, and determine the risks and benefits of the CGRP 
gepants (acute treatment) and CGRP mAbs (preventatives) to contribute to the existing 





Migraine is a primary headache disorder that causes excruciatingly painful 
headaches. Migraine can occur either with or without aura.  Utilizing the  International 
Classification of Headache Disorders, 3rd Edition (ICHD-3), migraine disorder without 
aura is characterized as a condition involving a “minimum of five attacks with at least 
two of the four characteristics: pulsatile quality, moderate to severe pain intensity, 
unilateral location, the condition is made worse by or causes a patient to avoid their 
customary physical activity, pain lasting from 4 to 72 hours, and is accompanied by at 
least one of the following symptoms of nausea and/or vomiting, photophobia , and 
phonophobia.” 2 Moreover, the ICHD-3 classifies migraine with aura as headaches that 
involve at least two attacks with  “one or more reversible aura symptoms: retinal, visual, 
speech and/ or language, motor,  sensory, and brainstem symptoms. Additionally, this 
disorder must also present with at least three of the following six characteristics: at least 
one aura symptom is positive (scintillations and pins and needles), a duration interval of 
5-60 minutes for each individual symptom, at least one aura symptom is unilateral, at 
least one aura symptom that spreads gradually over greater than 5 minutes, at least 2 aura 
symptoms that occur in succession, and the aura is followed by a headache within 60 
minutes of the attack.”2 Migraines are identified into 2 categories of migraine: chronic 
migraine or episodic migraine. Chronic migraine is characterized by an individual having 
15 or greater headaches per month, and episodic migraine is characterized by an 
individual having  less than 15 headaches each month. 2 
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         The  phases of a migraine are the premonitory phase, headache, postdrome, 
and aura phase.3 These phases can overlap as some symptoms can be found in multiple 
stages. 
 
Figure 1. Migraine stages. In this figure, it shows the various stages of migraine and symptoms 
found in each stage. Taken from (Ravishankar, Evans, Wang, 2016). 
Not all migraine patients will go through all four stages during each headache. An 
epidemiological study4 by Rasmussen and Olesen found that  32% of participants had 
migraine with aura amongst study subjects aged 25 to 64.  Premonitory or prodromal 
symptoms occur at least one to two days before the other symptoms of migraine with 
aura and can elicit difficulty in concentration, fatigue, sensitivity to light and/or sound, 
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neck stiffness, nausea, yawning, blurred vision, and pallor.1 Postdromal symptoms 
involve fatigue, impaired concentration and neck stiffness that may follow after a 
headache, and these symptoms can last up to 2 days.1 Symptoms in the postdromal phase 
can involve general, neuropsychiatric, sensory, and gastrointestinal symptoms and are 
experienced by 81% of migraine patients.5 It is known that the postdromal phase can 
increase the duration of the symptoms after a migraine headache, which can further 
contribute to disability among migraine patients.6 In the AMPP study7, 62.7 % of 
participants in the survey had migraine according to the ICHD-3 criteria. Participants 
were further classified into high frequency episodic migraine (HFEM), low frequency 
episodic migraine (LFEM), and moderate frequency episodic migraine (MFEM) groups 
depending on their monthly headache days (MHD). An increase in the number of 
migraines can cause significant disability, not only in the form of headache disability, but 
that this disability has a further correlation with one’s socioeconomic status as 
demonstrated by the AMPP survey. The AMPP survey found that as the MHDs increased 
the headache related disability that is assessed by the Migraine Disability Scale (MIDAS) 
increased linearly.7 In the HFEM group, participants had significantly greater headache 
disability than the LFEM or MFEM group. In addition to headache disability, participants 
in the HFEM group were reported to be 23% less likely to be employed part time or full 
time, and 19% less likely to report an annual household income of $60,000 or higher. 
Lack of treatment can also contribute to this disability and burden in those suffering from 
migraines. Researchers found that only 4.5% of patients could cross all 3 barriers in the 
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treatment of migraine: consultation, diagnosis, and treatment.8 Treatment for migraine is 
an unmet need for many in the United States as demonstrated by the AMPP study7. 
              The cause of migraines is not well understood.  Many scientists believe that 
there is a genetic component to this disorder. A population study9 found that less than one 
half of all migraine cases in the United States were due to familial factors such as 
environment related to family or genetic factors. Moreover, they reported an increased 
risk of developing migraine disorder in individuals with family members who had 
migraines, regardless of whether family member had migraine with aura or without aura9. 
While genetic factors do contribute to the likelihood of developing migraine, individuals 
who do not have family members with migraines can still develop migraine disorder. 
Ultimately, there are numerous factors both genetic and environmental that can increase 
the likelihood of migraine disorder in individuals.10   Migraines either present alone or 
can also occur alongside other preexisting conditions such as epilepsy, depression, and 
anxiety11. Stress, hormonal changes, and poor sleep hygiene may trigger migraines in 
some individuals 12.  Furthermore, some women experience migraines during their 










The current accepted theory on migraine pathophysiology is that migraine 
headaches are triggered by the Trigeminovascular system. In the brain, there are twelve 
cranial nerves. The fifth cranial nerve is known as the trigeminal nerve, it is involved in 
sensory perception to the head and face, and innervates the vasculature in the brain 13. 
The arteries within the brain contain various nerve fibers, but the sensory fibers are the 
most important to our discussion of the CGRP, as these fibers originate in the trigeminal 
ganglion and store the CGRP molecule. 14 CGRP is a peptide that is cleaved from the 
calcitonin gene. The CGRP molecule binds to its receptor, which is composed of both the 
CLR and a B type G protein coupled receptor connected to the RAMP1 protein. The 
CGRP molecule has been found in greater than 50% of trigeminal neurons, and it has 
been shown that there is a strong correlation between the CGRP release and an acute 
migraine attack.15 The amount of CGRP in the blood increases significantly and remains 
elevated in chronic migraine. 16 The CGRP peptide and the RAMP1 protein are found 
within the trigeminal ganglion and other brain regions14.  It is hypothesized that after the 
initiation of a migraine, the peripheral nociceptive trigeminal neurons relay a pain signal 






Figure 2. Pain Pathway for headache. This pathway displays the origin of migraine in the dorsal 
pons and the hypothalamus which will then activate the trigeminal ganglion leading to activation of the 
Trigeminovascular pain pathway. CGRP mAbs and CGRP gepants inhibit this pathway at the trigeminal 
ganglion, preventing further downstream effects in the pathway. Taken from (Edvinsson, 2018).  
 
Neuroinflammatory cytokines are released peripherally and then cross the blood 
brain barrier and trigger the central aspects of the Trigeminovascular pathway to cause 
the headache pain in the migraine (Figure 2). The idea that neuroinflammatory peptides 
take part in the initiation and potentiation of migraine headaches was crucial to the 
development of the CGRP inhibitors. While CGRP is involved in vasodilation centrally, 
the actual CGRP inhibitors do not appear to cross the blood brain barrier themselves as 
shown in Figure 2.  As such, the effect of the CGRP inhibitors on migraine is felt to 
occur by decreasing the release of CGRP peripherally from the trigeminal afferents. 
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The sites of migraine attacks occur within the temporal, parietal, and occipital 
lobes of the brain (Figure 3). 
 
Figure 3. Anatomy & Pathophysiology of Migraine. Panel A of this figure shows sites in the 
cortex where migraine attacks can occur.  There are many areas of the brain involved in the 
Trigeminovascular system, this can include areas of the brain that involve audition such as  the auditory 
cortex (Au). This system can involve parts of the brain involved with movement such as the secondary 
motor cortex (M2), secondary somatosensory cortex (S2) and the primary motor cortex (M1), and the areas 
involved with vision such as the primary visual cortex (V1) and secondary visual cortex (V2). Other areas 
involved with this system are the parietal association cortex (PtA) and the primary somatosensory cortex 
(S1).  In Panel B, the signaling pathway involved in migraine is displayed, as well as how various 
medications affect this pathway such as Cilostazol, Levcromakalin, Sildenafil, and Nitroglycerin. Notable 




The major site of action of both CGRP inhibitors and CGRP mAbs are mainly in 
the trigeminal ganglion and the dura mater 14 (Figure 4).  
 
Figure 4. The areas of effect of CGRP Inhibitors and CGRP mAbs. In this figure, CGRP 
inhibitors and CGRP mAbs block CGRP responses that lead to vascular responses, and may block the 
transmission of pain commonly experienced in migraine. Taken from (Edvinsson, 2017). 
Treatment  
A new target for both acute treatment and prevention of migraine is the Calcitonin 
gene-related peptide. The CGRP mAbs are a novel class of medication developed 
specifically for migraine prevention, in contrast to previous preventative medications, 
that were in the anti-hypertensive, anti-epileptic and anti-depressant classes.  There are 
two notable divisions within the CGRP inhibitor class: CGRP mAbs and the gepants. 
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There are 4 CGRP mAbs that have been approved for the prevention of chronic and 
episodic migraine: Vyepti (eptinezumab), Aimovig (erenumab), and Ajovy 
(fremanezumab), Emgality (galcanezumab). The current FDA approved gepants are 
Ubrevly (ubrogepant) and Nurtec ODT (rimegepant). This class of drug targets the CGRP 
peptide itself (CGRP antagonists) or the CGRP receptor (CGRP receptor antagonists). 
These medications inhibit the action of CGRP, which is one of the neuroinflammatory 
peptides found to play a role in migraine pathophysiology.  
Migraines have been treated with various preventative and acute medications over 
the years. The various treatments for migraine vary by cost, with some on the low end of 
the cost spectrum such as aspirin and caffeine, to the high end with medications such as 
OnabotulinumtoxinA (Botox).  
Pathophysiology of Medications 
CGRP mAbs are approved for treatment of episodic and chronic migraine. They 
treat migraine with or without aura. 14 They are also beneficial as they do not cause 
vasoconstriction with use like some other acute treatment options for migraine, such as 
the triptan class.14 CGRP mAbs are especially attractive for patients who have not found 
prior treatment trials to be successful, or have preexisting health conditions such as heart 
disease, coronary artery disease, and vascular disease. CGRP mAbs can aid in decreasing 
the frequency, severity, and duration of migraines. Erenumab is the only 100% 
humanized CGRP mAbs. Erenumab works by binding to the canonical CGRP receptor, 
which prevents the docking or binding of CGRP. The other mAbs work by binding to the 
CGRP peptide itself.  As they are specific in their target, the CGRP mAbs also tend to be 
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better tolerated with fewer side effects than more traditional, oral preventatives, which 
can lead to improved compliance.19   
OnabotulinumtoxinA (Botox) 
 The proposed underlying pharmacological mechanisms leading to migraine relief 
with Botox use will now be examined to compare the effectiveness between Botox and 
the CGRP mAbs. One theory is that Botox therapy decreases release of 
neuroinflammatory peptides, such as CGRP, from the trigeminal ganglion, leading to a 
decrease in peripheral and central responsiveness to stimuli that would initiate a 
migraine.20,21 Additionally, Botox may decrease peripheral responsiveness by interfering 
with sensory receptors and ion channels (TRPV1)21 on the ends of nociceptive neurons.20  
The trigeminal ganglion has an integral role in migraine pathophysiology and its 
numerous functions:  receptor sites for triptans and CGRP inhibitors, involvement pain 
information transmission, and it innervates the vasculature within the brain that responds 




Figure 5. Pharmacological Mechanisms. Various pharmacological mechanisms of the CGRP 
mAbs, CGRP inhibitors, and the Triptans. Triptans block the release of the CGRP molecule from 
varicosities on the trigeminal nerve. CGRP inhibitors or Gepants block the CGRP receptor, and the CGRP 
mAbs can either target the CGRP molecule (Anti-CGRP antibody) or the CGRP receptor (Anti-CGRP 
receptor antibody). Taken from (Edvinsson, 2018). 
Triptans 
Triptans are medications created for the acute treatment of both migraine with and 
without aura.  Triptans function as serotonin agonists, which target the presynaptic 
serotonin receptors, specifically 5-HT 1B and 1D, to inhibit CGRP release 20(Figure 5). 
Through this mechanism, triptans can prevent increases in plasma CGRP that lead to 
development of a migraine, and resolve pre-existing acute migraine attacks.  
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        While effective acute treatment agents, triptan use is contraindicated in certain 
patient populations, such as those with coronary artery disease, due to their 
vasoconstrictive properties. Currently, there are 7 FDA approved triptan agents: 
Sumatriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan, naratriptan and 
frovatriptan. This thesis will discuss sumatriptan in comparison to the CGRP receptor 
antagonists (gepants) for acute migraine treatment.  
Table 1. CGRP Monoclonal Antibodies25, 26, 27, 28. 
Drugs Dosage How many 
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*CGRP Inhibitors have not been shown to have any serious adverse vascular events in people taking the 
medication.24 
** Some individuals may experience hypertension as demonstrated in physician case reports submitted to 
the FDA Adverse Event Reporting System website. 62 There are no known drug interactions. Due to lack of 
data, discontinuation in pregnancy and during lactation is recommended.   
Erenumab does not appear to cause severe vascular adverse events in participants when 
compared with placebo. In a randomized controlled trial, researchers studied the efficacy 
of erenumab on participants who had stable angina due to coronary artery disease 
(population with high cardiovascular risk) who exercised on a treadmill.24 Researchers 
measured the effect of erenumab on time until an individual develops exercise induced 
angina and total exercise time. 24 Researchers found that erenumab did not severely 
decrease exercise time and myocardial ischemia did not worsen in these patients.   
Table 2. Small Molecule CGRP Receptor Antagonists (gepants) 29, 30 
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Specific Aims  
1. Review the literature on previous migraine treatments, specifically 
sumatriptan and Botox 
2. Investigate current studies involving the CGRP mAbs and small molecule 
CGRP receptor antagonists (gepants) 
3. Conclude whether the CGRP inhibitors are more effective than 






A. Acute Treatment 
Episodic migraine is characterized as having less than fifteen attacks per month, 
with an attack duration of between 4 and 72 hours.1 Chronic migraine is characterized as 
having fifteen or more migraine attacks per month, in accordance with the ICHD-3 1To 
be included in the following studies, participants must have had migraine for a minimum 
of one year, with at least 2 to 8 attacks ranging from moderate to severe intensity over a 
period of three months before the clinical trial.34,35, 36. Response to treatment was 
recorded in most studies via an electronic diary. The first primary endpoint of these 
studies was absence of the most bothersome migraine-associated symptom (MBS) which 
includes phonophobia, photophobia, or  nausea at two hours and the second endpoint is 
freedom from pain at two hours after the initial dose. In research studies assessing acute 
migraine treatments, placebo was often in the form of sugar pills or saline injections. An 
end point or measure is a dependent variable in these trials. 
ACHIEVE  I Trial 
In the ACHIEVE I Trial, researchers assessed the effectiveness of ubrogepant in 
the acute treatment of episodic migraine without or with aura in adults.37 The co-primary 
endpoints  were MBS at 2 hours, and freedom from pain at 2 hours. Secondary endpoints 
involve sustained pain relief for 24 hours, sustained pain freedom for 24 hours, pain relief 
at 2 hours, and absence of nausea phonophobia, and photophobia at 2 hours. The 
methodology design of the ACHIEVE I Trial was to randomly assign participants to each 
of the three study conditions: Placebo, 100 mg or 50 mg of ubrogepant.3 Each participant 
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used ubrogepant to treat one moderate to severe intensity migraine headache. Participants 
could elect to take either their own rescue medication (NSAID, acetaminophen, anti-
emetic, triptan or narcotic) within 2-48 hours after the initial study dose if needed or a 
second randomized study dose (placebo or active). Participants taking placebo would get 
a second dose of placebo, while participants taking ubrogepant were randomly assigned 
to placebo or the same dose of ubrogepant the participant had taken for the first dose. The 
study excluded women that were pregnant, and any participant who had chronic 
migraines, any participants that did not use the medication within 60 days of starting the 
study, individuals who could not distinguish migraine from tension type headaches, 
individuals who used acute medications more than 10 days in a month, previous 
participants of a CGRP mAbs trial, and individuals with cardiovascular or 
cerebrovascular disease. This study allowed patients to continue preventative treatment 
for their migraine, including those with a prior history of chronic migraine and their 
chronic migraine was well controlled with fewer than 15 headaches per month. The 
duration of this study was approximately 1 year and 5 months, and included women and 
men from age 18 to 75. The study consisted for 4 clinic visits. The first visit was for 
screening, and the second visit was for randomization. The third visit occurred 2 to 7 
days after participants treated their qualifying migraine attack. Researchers then 
performed a follow up phone call within 2 weeks of the study drug dose, and a fourth 
safety visit was performed 4 weeks after the initial dose was taken.  
ACHIEVE II Trials 
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In the ACHIEVE II Trial38, researchers tested ubrogepant to determine its efficacy 
in the acute treatment of migraine in adults who had episodic migraine with or without 
aura. The co-primary study endpoints were similar to ACHIEVE I in that ACHIEVE II 
also assessed MBS at 2 hours and the freedom from pain at 2 hours. Secondary endpoints 
included absence of photophobia, nausea, and phonophobia at 2 hours, pain relief at 2 
hours, sustained pain freedom for 24 hours, and sustained pain relief for 24 hours.   In the 
ACHIEVE II Trial participants were placed to one of the three study conditions: 25 mg 
and 50 mg of ubrogepant and placebo. In this study, each individual utilized ubrogepant 
to treat one migraine headache of moderate to severe intensity. Participants had the 
option to take either a second randomized study dose (ubrogepant or placebo), or their 
own rescue medication (NSAID, acetaminophen, anti-emetic, triptan or narcotic) within 
2-48 hours of the initial study dose if needed. Participants in the placebo group would get 
a second dose of placebo, while the ubrogepant group was randomly assigned placebo or 
the same dose of ubrogepant the participant had taken for the first dose. The study 
excluded women that were pregnant, any participants who had chronic migraines, any 
participants that did not use the medication within 60 days of starting the study, 
individuals who could not distinguish migraine from tension type headaches, individuals 
who used acute medications more than 10 days in a month, previous participants of a 
CGRP mAbs trial, and those with clinically significant cardiovascular or cerebrovascular 
disease. This study allowed patients to continue preventative treatment for their migraine, 
including those with a prior history of chronic migraine who were well controlled with 
fewer than 15 headaches per month. The duration of this trial was approximately 1 year 
 
20 
and 6 months, and included males and females that had an age range of 18 and 75. The 
study consisted for 4 clinic visits. The first visit was for screening, and the second visit 
was for randomization. The third visit occurred 2 to 7 days after participants treated their 
qualifying migraine attack. Researchers then performed a follow up phone call 14 days 
after the study drug dose was taken, and a fourth safety visit was performed 4 weeks after 
visit 3.  
ACHIEVE Trial Pooled Analysis 
Three exploratory end-points were also assessed in a study comparing patient 
reported ability to function, global impression change, satisfaction with ubrogepant in 
ACHIEVE I and ACHIEVE II. 39  The Functional Disability Scale39 used ranges from 0 
(able to finish tasks normally without impairment) to a score of 4 (the pain was so severe 
participants were not able to complete their daily tasks, and were on bedrest). Another 
measure was the Satisfaction Measure, in which participants were asked how satisfied 
they were with the medication on rating scale with 7 points. A higher number value on 
this scale indicated more satisfaction. The third scale was the Patient Global Impression 
of Change Scale, which is another seven-point scale, however this scale goes from 0 
(very much better) to 6 (very much worse). 
Rimegepant vs. Placebo 
In a randomized and double blind clinical trial conducted by Croop et al. (2019)40,  
participants were administered 75 mg of rimegepant or placebo. This clinical trial shares 
the same inclusion and exclusion criteria as the previously mentioned randomized control 
clinical trials involving ubrogepant. Participants included individuals with episodic 
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migraine as defined by the ICHD31, and excluded participants that had participated in 
other CGRP mAbs trials, or had significant cardiovascular and cerebrovascular disease. 
The co-primary endpoints were freedom from their most bothersome symptom associated 
with the migraine condition (nausea, photophobia, phonophobia) and freedom from pain 
at 2 hours’ post-dose. Researchers organized the secondary endpoints into categories, the 
first which involved the ability to function at 2 hours post dose, freedom from 
photophobia, freedom from phonophobia, freedom from nausea, and pain relief, The 
second category involved freedom from most bothersome symptom, freedom from pain, 
ability to function normally and pain relief at 90 minutes. The third category involved 
sustained freedom from the most bothersome symptom, sustained pain freedom from 2 to 
24 hours and 2  to 48 hours post-dose, sustained pain relief, sustained ability to function 
normally, probability of rescue medication use within 24 hour of dosing, and pain relapse 
from 2 to 48 hours post-dose. 669 patients were placed into the rimegepant group and 682 
patients were placed to the placebo condition for a total of 1351 participants. The average 
age of the participants were 40 years old, and most of the individuals in the study were 
women. This trial and a long-term safety study41 of rimegepant were pivotal trials leading 
to FDA approval.  
Rimegepant Long-Term Safety (Study 201) 
Study 201 is a long term, open label, safety study.41 In this study, participants 
experienced 2-14 migraine attacks per month meeting ICHD-3 criteria for episodic 
migraine with or without the presence of aura. Participants in the  main enrollment group 
were instructed to take up to 1 tablet per day as needed to treat headache pain of any 
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severity for up to 52 weeks. The study also included a subgroup of participants with 4 to 
14 migraines with moderate/severe attacks per month.  This subgroup was instructed to 
take 1 tablet of rimegepant 75mg every other day for 12 weeks, with the option of taking 
an additional as needed dose of Rimegepant for migraine headache on non-scheduled 
dosing days. Over the duration of this study, participant usage, migraine frequency, 
disability, and safety were assessed. The primary end points for this study were safety and 
tolerability, and these end points were measured in the enrollment group and overall group. 
This study measured frequency and severity of adverse events that occurred in greater than 
5% of participants, severe adverse events, and any lab abnormalities.  
Rimegepant vs. Sumatriptan vs. Placebo 
Rimegepant (BMS-927711) was compared with placebo to determine its efficacy 
in  acute migraine treatment.42 This study is different from the previous rimegepant study 
in that this study is a dose-ranging trial. Sumatriptan was utilized as an active comparator 
in this study, and as such, researchers did not make a direct comparison between the 
efficacy of sumatriptan and rimegepant. Participants were randomized into one of eight 
possible groups where they received either placebo, sumatriptan 100 mg tablet, or one of 
six possible rimegepant treatment doses (10, 25, 75, 150, 300 or 600 mg). Each 
participant was able to treat one migraine attack with their study dose. The primary 
outcome was to measure the number of patients that achieved pain freedom two hours 
post-dose with the study drug in comparison to pain freedom achieved in participants 
taking placebo. Participants rated the intensity of their pain on a 4-point scale (no pain, 
severe pain, moderate pain, and mild pain). The secondary measures of this study were 
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complete migraine freedom (including non-pain associated symptoms such as 
photophobia, phonophobia, and nausea) at 2 hours post dose, and sustained pain freedom 
from 2-24 hours post dose.  The sample size of the study was 885 patients, and included 
both sexes, aged 18 to 65 yrs. Participants were excluded from the study if they had 15 or 
more headache days per month, history of significant psychiatric or neurological disease, 
a history of basilar or hemiplegic migraine, stroke/transient ischemic attack, significant 
cardiovascular disease, drug/substance use within the prior 12 months, were resistant to 
triptan medications, were on CYP3A inhibitor, were on medications that could alter 
stomach pH such as antacids, had a history of non-narcotic analgesic use of 15 days per 
month for 3 months, or had a history of triptan or ergotamine use greater than 10 days per 
month for 3 months.  This study included patients that had a history of at least one year of 
episodic migraine per ICHD-3 criteria 1, with a minimum of 2 attacks and maximum of 8 
attacks and these attacks have a range of intensity from moderate to severe each month 
within the last 3 months.  After randomization, participants were further excluded if they 
did not follow  medication or study protocols, were lost to follow up, or became pregnant.  
Ultimately, 799 participants finished the study and were included in the analysis of 
efficacy. 
Sumatriptan vs. Placebo 
 
In this study, sumatriptan was compared with placebo to determine the efficacy of 
sumatriptan in treating acute migraine in treating one migraine attack. This study was 
composed of two individual studies that were identical in that they were double blind, 
randomized, and  placebo-controlled. The study involved participants from the ages of 
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18-65. 43 Participants were given a placebo dose, 100 mg of sumatriptan, 50 mg of 
Sumatriptan, to take when they felt the first sign of migraine pain. The primary endpoint 
was to assess pain-free relief (the severity of the headache is reduced to 0) at 2 hours after 
treatment with 50 mg of sumatriptan in comparison to placebo. Secondary end points 
were pain-free relief 2 hours after taking the 100 mg of sumatriptan, migraine-free relief 
(freedom from pain and associated symptoms) 2 and 4 hours after treatment, and the 
percentage of patients with pain-free relief 4 hours after taking 50 mg and 100 mg of 
Sumatriptan.  To be included in this study, patients had to have experienced a mean of 1 
to 6  migraine attacks monthly for at least 2 months before the study period began.  
B. Preventative Treatment 
 
Erenumab vs. Placebo LIBERTY Trial 
In the LIBERTY trial, researchers evaluated the efficacy of erenumab compared 
to placebo for the treatment of episodic migraine with and without aura. This clinical trial 
lasted 12 weeks, and participants were screened with an established baseline of 4 weeks 
prior to participation in the study.44 Participants were 18-65 years of age, and must have 
had episodic migraine for at least 12 months before study. Participants included those 
who had previously failed 2 to 4 previous migraine prevention treatments, participants  
not included in pivotal trials to avoid negative or unwanted study results and refractory 
patients. The primary endpoint was the number of patients that were able to achieve a 
fifty percent or greater reduction in their average number of migraine days per month 
during the weeks of  9 to 12 weeks in the study. Secondary efficacy endpoints  assessed 
in this trial were measuring the number of patients with a 75% or more reduction from 
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baseline in the monthly migraine days experienced by participant, change from a 
participant’s baseline in the number of monthly migraine days, change from baseline in 
scores on the activities of the Migraine Physical Function Impact Diary, and the change 
in monthly use of acute migraine treatment in comparison to baseline. 
Participants received two subcutaneous injections of placebo or erenumab (total 
of 140mg). Participants underwent treatment on the first day, this treatment was followed 
up with one treatment every 4 weeks for a duration of 12 weeks. Patients were assessed 
with the participant-reported outcome questionnaires, Work Productivity and Activity 
Impairment, Headache-Impact Test, EQ-5D-5L, Beck Depression Inventory64, and the 
Migraine Physical Function Impact Diary. Researchers followed up with participants 
which occurred once every 4 weeks during the study, and included blood pressure, 
electrocardiography, and lab work. 
Erenumab vs. Placebo STRIVE Trial 
The STRIVE trial had two phases which involved a 24-week double blind study 
phase, and then lead to an open label phase that had a duration of 28 weeks. 45 In this 
study, participants received  either placebo, 70 mg or 140 mg of erenumab, and were 
assessed for 6 months for the treatment of episodic migraine. The primary end point for 
this trial was to assess the change in the number of migraine days per month at months 4 
to 6 compared to baseline. Secondary endpoints included improvement in the average 
number of migraine days each month (measured by a fifty percent reduction or more), 
change in scores on activities of the Migraine Physical Function Impact Diary (scores 
range from zero to hundred), and difference in the average number of days a participant 
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utilized acute treatment to reduce migraines. Higher scores on the Migraine Physical 
Function Impact Diary indicate that the migraine has a larger burden on the individual.  
Erenumab vs. Placebo ARISE Trial 
The ARISE clinical trial lasted 12 weeks and had a  randomized, placebo-
controlled, and double blind trial phase with a subsequent 28-week open label phase. In 
this clinical trial, received either placebo or 70 mg of erenumab to assess drug efficacy in 
the prevention of episodic migraine. The primary endpoint was to evaluate the change in 
mean monthly migraine days at 12 weeks compared to baseline.46 Secondary endpoints 
were greater than a 5-point reduction in score on activities measured by the Migraine 
Physical Function Impact Diary, change in acute migraine-specific medication treatment 
days, and more than fifty percent reduction in monthly migraine days. All of the 
endpoints in this study analyzed change in migraine days measured at baseline to change 
in migraine days up to month 3.  
Open Label Erenumab Study 
This  was a five year, open label study to determine the safety of erenumab. At the 
time of this thesis the study has completed, but only the first three years of data have been 
published for review.  61 Participants were initially given subcutaneous injections of 70 
mg of Erenumab once monthly, and after a protocol amendment after the second year, 
doses were increased to 140 mg of erenumab monthly. Safety of the drug was assessed 
through regular electrocardiograms, laboratory assessments, and vital signs.  
Botox vs. Placebo PREEMPT1 Trial 
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The PREEMPT1 clinical trial had 2 phases, the first phase was a double blind, 
parallel-group, placebo-controlled phase lasting 24 weeks, and the second phase was an 
open label phase with a duration of 32 weeks. 48 Participants received either  a series of 
placebo injections or injection with onabotulinumtoxinA (Botox) once every 12 weeks 
(155U to 195 U). Participants completed two cycles of either placebo or Botox as part of 
the blinded portion of the trial. Researchers wanted to determine differences in the 
headache episode frequency at the twenty-fourth week compared to baseline. The 
secondary endpoints were the migraine days, frequency of headache days, overall pain 
medication use, and migraine episodes. In the PREEMPT1 clinical trial, the inclusion 
criteria required participants to be diagnosed with chronic migraine and were required by 
investigators to record information about the number of headache episodes from the trial 
on 20 or more days during the baseline period of the study. Participants were excluded 
from the trial if study participants had a condition that could be contraindicated with 
Botox such as other primary or secondary headache disorders, a Beck Depression 
Inventory64 score of greater than 24, psychiatric disorders, previous use of prophylactic 
medication before study, and pregnancy.  
Botox vs. Placebo PREEMPT2 
The PREEMPT 2 clinical trial was similar to PREEMPT 1 in terms of the trial 
being a double blind, placebo-controlled phase, and parallel-group and having a duration 
of 24 weeks followed by a 32-week open label phase. 49Participants received either a 
series of placebo injections or an injection with onabotulinumtoxinA (Botox) once every 
12 weeks (155U to 195 U) for two cycles. To note the primary endpoint for this study 
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was changed after study initiation by protocol amendment from frequency of headache 
episodes to frequency of headache days per 28 days from baseline to weeks 21 to 24 
treatment. The secondary endpoints were frequency of moderate/severe headache days, 
frequency of migraine days, monthly cumulative headache hours on headache days, 
frequency of headache episodes, and the number of patients with severe Headache Impact 
Test (HIT)-6 score. Similar to PREEMPT1, PREEMPT2 excluded participants that had 
other primary or secondary headaches, neuromuscular diseases, previous usage of 
prophylactic medication, or a Beck Depression Inventory score of greater than 24 at 
baseline. The participants that were included were those that have been diagnosed with 
migraine of greater than 15 days a month, which is the criteria for a chronic migraine 
diagnosis.  
Botox vs. Placebo COMPEL 
In this clinical trial, patients with chronic migraine were given 155 U of 
OnabotulinumtoxinA (Botox) once every 12 weeks per PREEMPT protocol (155 units at 
31 sites) for nine cycles of treatment.50 The primary  endpoint was reductions in headache 
days at 108 weeks. The secondary endpoints were change in the 6-item Headache Impact 
Test (HIT-6) score and reductions in headache days at 60 weeks. Adverse events were 
also assessed at each visit by patient self-report, non-directed questioning, and a physical 
exam. Participants were excluded if they had suicidal ideation, severe major depressive 
disorder, had previously used Botox, or did have chronic migraine. Participants included 




Botox vs. Erenumab 
 This study was a prospective open label study of patients who did not have 
greater than 30% improvement in treatment, or could not tolerate Botox therapy for 
chronic migraine prevention.54 Participants received erenumab for chronic migraine 
prevention, and were assessed on a monthly basis. The patients recorded their findings in 
an electronic diary in which they recorded their severity of the headache and their pain. 
Participants rated their pain severity with colors. In this study, amber days represented 
days where headaches did not hinder an individual’s daily activities, green days 
represented days in which the individual had headache-free days, and the red days 
represented days where an individual’s daily activities were limited and the individual 
had to utilize triptan to reduce the headaches. Patients also completed questionnaires such 
as the pain disability index(PDI), patient health questionnaire (PHQ-9), headache impact 
test 6 (HIT-6), and recorded the number of days an individual used triptans and other 
painkillers54.  In the initial study, all patients took a 70-mg dose that was administered 
subcutaneously once per month. After two months, researchers followed up with the 
participants by phone. Participants were given the option to increase their 70-mg dose to 
140 mg dose as long as they did not experience any side effects noted as secondary to 
erenumab. Patients were could  increase the dose of their medication from 70 mg to 
140 mg unless they experienced side effects. The duration of this study lasted 9 months, 
and had 98 subjects. Ultimately, 24 patients discontinued erenumab during the study, 
mainly due to lack of perceived benefit or side effects (rash, hypertension, palpitations, 
gastrointestinal upset, throat tightness).  At the time of analysis, only 27 participants had 
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completed the full 9 months of treatment, while 44 participants were at differing points in 





ACHIEVE I & II Trials (Ubrogepant vs. Placebo Study) 
There were 1672 participants in the ACHIEVE I trial and 1686 participants in the 
ACHIEVE II Trial. 345 participants and 232 participants were excluded from efficacy 
analysis in the ACHIEVE I and ACHIEVE II trials respectively due to deviation from 
study protocol. Participants were removed if they were lost to follow up, did not follow 
experiment protocol, became pregnant, or had a serious adverse reaction (spontaneous 
abortion, appendicitis, seizure, and pericardial effusion). These serious events happened 
within 30 days of the trial.  
ACHIEVE I Trial Efficacy 
The average age of the participants in the ACHIEVE I trial was 41 years old. In 
this trial, of the total participants 88.2 % were women, 82.5 % of the participants were 
Caucasian. 37 Of the remaining participants 0.01% were Asian American, 11% Hispanic 
or Latino, 13% were African American. Before the study, 56.4% of the participants 
reported photophobia as their most bothersome symptom, and a little over 22.8% of the 
patients were on preventative treatment for migraine. Both the ubrogepant 50 mg dose 
and  100 mg dose achieved pain freedom at 2 hours compared to 11.8% of individuals 
receiving placebo; 21.2%  of participants that received the 50 mg dose (p<0.001)  and 
19.2% of participants that received the 100 mg dose (p=0.002). More participants in the 
50 mg than the 100 mg group ubrogepant group reported MBS. At 2 hours, the 
percentage of individuals who had freedom from the most bothersome symptom was 
37.7% in the 100mg ubrogepant (p=0.002), 38.6% of participants in the 50 mg dose  
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ubrogepant group (p=0.002), and 27.8% in the placebo group. in both the 50 mg and 100 
mg ubrogepant study group, only 38.6% took the optional second dose. Only a fourth of 
the individuals who took the second dose, took a second dose of ubrogepant. The number 
of participants that used rescue medications after the optional second study dose were 9% 
in the 50 mg dose group, 21.1% in the placebo group, and 10% in the 100 mg dose group. 
Both 100 mg and 50 mg participants experienced statistically significant relief from pain 
at 2 hours and sustained pain relief from 2-24 hours compared to placebo. Only the 100 
mg dose achieved statistically significant freedom of pain from 2-24 hours compared to 
placebo. 
ACHIEVE II Trial Efficacy 
1355 participants received ubrogepant in the ACHIEVE II trial. 90% of 
participants were women and the mean age of participants was 42 years. 38 At 2 hours, 
14.3% of individuals in the placebo group reported pain freedom, 21.8% (p=0.01), and 
20.7% (p=0.03) of participants in the 25 mg and 50 mg ubrogepant groups respectively.  
MBS at 2 hours was reported by 27.4% in the placebo group (P=0.07), 38.9% of 
participants in the 50 mg dose ubrogepant group (P=0.01), and 34.1% in the 25 mg group 
ubrogepant group (P=0.07). The most common adverse events reported within 48 hours 
of any dose by individuals in this study were nausea and dizziness. Next, this thesis will 
discuss a study comparing the results of the ACHIEVE I and ACHIEVE II trials.  This 




Figure 6. Participants With Normal Function. The percentage of participants that had a normal ability to 
function after taking placebo or 50 mg ubrogepant dose. For the 50mg dose, at 2 hours 40.6% (p<0.0001) 
of participants across the ACHIEVE 1 and 2 trials reported normal functioning after a migraine attack.  At 4 
hours, the number of participants increased to 60.7% (p<0.0001) of participants, and had a 16.3% increase 






Figure 7. Participant Satisfaction Pooled. The pooled data of the percentages of participants that were 
either “satisfied” or “extremely satisfied” with the placebo or ubrogepant 50 mg at 24 hours and 2 hours 
after the first dose of medication.  In both the ACHIEVE trials a larger percentage of participants found 
satisfaction with ubrogepant 50 mg compared to placebo at both 2 and 24 hours.  In the pooled data for 
placebo and ubrogepant 50 mg, participant satisfaction rate doubled from 61.2% (p<0.0001) at 24 hours 
after the initial dose when compared to 37.1% (p<0.0001) satisfaction rate with ubrogepant at 2 hours. 
 
 
Figure 8. Participant Feelings Pooled. The results of the Patient Global Impression of Change (PGIC) 
scale, in which the participants reported how well their migraine symptoms were relieved. Results are 
pooled from the ACHIEVE Trials for placebo and the ubrogepant 50 mg dose, with participants giving 
descriptions in the improvement of pain as “much better” or “very much better” at 2 hours post-dose 
(p<0.0001).  In the ACHIEVE 1 trial, the 34.3% (p=0.0009) of participants noted that their migraine was 
improved at 2 hours post-dose with the 100 mg dose of ubrogepant. 
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ACHIEVE I and ACHIEVE II Safety 
Symptoms most commonly reported by the study participants in the ACHIEVE 
trials were nausea, dizziness, somnolence, and dry mouth.39 More participants in the 100 
mg ubrogepant group experienced these symptoms than other groups. Serious adverse 
events reported in the ACHIEVE I trial included 2 participants with appendicitis, 1 
seizure, 1 spontaneous abortion, and 1 pericardial effusion. Of the above adverse events 
only one that was felt to be potentially related to the trial, and was a seizure in a 
participant who received 100 mg of ubrogepant.  There were no serious adverse events 
related to ubrogepant that were reported in the ACHIEVE II trial. These serious events 
happened after the 48 hours. Side effects were similar between both trials overall, with 
nausea being reported most commonly.  4 participants in ACHIEVE II and 6 participants 
in the ACHIEVE I trial had elevated post-baseline AST and ALT levels, but were felt to 
be unrelated to ubrogepant on independent review due to confounding patient factors.  
Rimegepant vs. Placebo Efficacy 
The study by Croop R et al. 40  focused on assessing the efficacy of rimegepant 
compared to placebo for the acute treatment of migraine. In this study, 21% of 
participants were African American, 74% were Caucasian, and 1% were Asian or 
American Indian/Alaska Native. 17% of study participants further identified as Hispanic 
or Latino. This study found that rimegepant was more effective than placebo for freedom 
from pain at 2 hours post-dose in 11% of participants in the placebo group compared to 
21% in the rimegepant group (p<0.0001). Compared to 27% of participants in the  
placebo group (p=0.0009), 35% of participants in the rimegepant group also experienced 
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freedom from their most bothersome symptom at 2 hours.  The most common adverse 
events were urinary tract infection and nausea.   
Rimegepant vs. Placebo Safety 
In (Study 201)41, adverse events were reported by 60.4% of subjects. The most 
common adverse events were nasopharyngitis (6.8%), upper respiratory tract infection 
(8.8%), and sinusitis (5.1%).  Only 2.7% of participants discontinued the treatment with 
rimegepant due to an adverse event. With regards to liver toxicity, 1.0% of participants 
reported ALT or AST levels that were greater than 3 times ULN during treatment, but 
researchers determined that these cases were not related to the use of rimegepant in the 
trial. This study suggests that 75 mg of rimegepant is well-tolerated by participants  and 
does not appear to show signs of liver toxicity.  
Rimegepant vs. Sumatriptan vs. Placebo Efficacy 
In this study, sumatriptan was only included as an active control for the sensitivity 
assay, and the main goal of the study was to assess the efficacy of rimegepant at different 
doses compared to placebo. The study showed that rimegepant doses of 75 mg, and 
higher were more effective at achieving pain freedom at 2 hours post dose compared to 
placebo.  The Bayesian model revealed that the most effective dose of rimegepant was 
150 mg, with  32.9% (p<0.001) of individual who were free from pain 2 hours after the 
initial dose of medication.42 Of the secondary endpoints using the Bayesian model, the 75 
mg dose was found to be most effective at achieving complete migraine freedom at 2 
hours post dose (28.2%, p<0.001). Total migraine freedom at two hours post dose was 
 
37 
23.4% in the 300 mg rimegepant group, 27.9% in the 75 mg rimegepant group, 25.9% in 
the 150 mg rimegepant group, and 11.8% of patients in the placebo group.  
Rimegepant vs. Sumatriptan vs. Placebo Safety 
The most common reported side effect was nausea, which increased in 
participants as the dosage of rimegepant increased. In the sumatriptan group, two 
participants experienced chest discomfort, with chest pain, muscle tightness, and jaw pain 
also reported. Participants in all groups (placebo, sumatriptan, and rimegepant) reported 
nausea, dizziness, and vomiting. Diarrhea and nausea were also reported in some patients 
receiving rimegepant. There were no reported ECG abnormalities in either the 
rimegepant or sumatriptan groups. Two patients had an increase in hepatic enzymes, one 
in the 75 mg rimegepant group and the other in the placebo group. No patient had alanine 
aminotransferase (ALT) levels that were 3 times greater than the normal upper limit. One 
participant in the placebo group had a bilirubin that was two times greater than the upper 
limit. 
Sumatriptan vs. Placebo Efficacy 
A large proportion of patients that received sumatriptan  50 mg dose or  100 mg 
dose were free from pain 2 and 4 hours after treatment compared to patients that received 
placebo at 2 hours and this increase continued as the time increased (p<0.001).43 There 
were 57% of participants in the 100 mg Sumatriptan group compared to 50% of 
participants in the 50 mg group. Furthermore, there was a significant percentage of 
patients treated with Sumatriptan 50 mg and 100 mg that were migraine-free (no pain or 
associated symptoms) at 2 and 4 hours after treatment. The results showed that at 2 hours, 
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49% of participants in the 100 mg group(p<0.001)  43% of participants in the 50 mg 
group (p<0.001) were migraine free.  At 4 hours, there were 63% of participants in the 
100 mg group and 54% of participants in the 50 mg group that were migraine-free 
(p<0.001). The reported adverse events were low overall in all participant groups in this 
study. The study results concluded that sumatriptan 50 mg and 100 mg were more 
effective than placebo at acute migraine treatment, and suggested that sumatriptan 100 
mg may be more effective than 50 mg when taken early, but was not powered to detect 
statistical differences between active medication doses. This means that we cannot 
directly say that 100 mg is more effective than 50 mg as the study was not designed to 
compare these two doses to each other. 
Sumatriptan vs. Placebo Safety 
In patients taking sumatriptan, the main adverse events were nausea, vomiting, 
dizziness, vertigo, malaise, fatigue, injection site reactions, heaviness, pressure, feelings 
of warmth, and headache.44 3 to 5% of participants experienced pressure and warmth in 
the chest, but these symptoms were not found to be associated with cardiac dysfunction. 
Erenumab vs. Placebo LIBERTY Trial 
246 participants were randomized into 2 groups: the erenumab group and the 
placebo group. There were 125 participants that took placebo and 121 participants that 
took erenumab. At baseline, the average number of migraine days per month were 9.3 in 
the placebo group and 9.2 in the erenumab group.  At 12 weeks, 14% of participants in 
the placebo group and  30% of participants in the erenumab group had a fifty percent or 
greater reduction in the monthly number of migraine days(p=0.002).45 At 12 weeks, 4% 
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of study subjects in the placebo group and 12% of study subjects in the erenumab group 
had a 75% or greater reduction in their monthly number of migraine days (p = 0.025). At 
12 weeks, more patients in the erenumab study group a fifty percent or greater reduction 
from baseline in the mean number of monthly migraine days than the patients in the 
placebo group. Overall, erenumab resulted in about 2 additional headache free days per 
month compared to placebo.   
Erenumab vs. Placebo Safety 
 The most frequent adverse events were nasopharyngitis, injection site pain, and 
back pain. One serious adverse event reported in the erenumab group was a traumatic 
orbital fracture that was unrelated to the use of erenumab. One serious adverse event 
(gastrointestinal infection) was reported in the placebo group, also unrelated to the study 
drug.  
Erenumab vs. Placebo STRIVE Trial 
 The STRIVE trial demonstrated that at baseline the mean number of migraine 
days each month were 8.3 in the study participants. Both erenumab doses in 70 mg and 
140 mg proved effective at decreasing the number of migraine days. For instance, the 
participants that were selected to use the 70 mg of erenumab reported a 3.2 less migraine 
days, and participants selected to use the 140 mg of erenumab reported 3.7 less migraine 
days (p<0.001) 45. The placebo was not as effective as participants reported 1.8 less 
migraine days (p<0.001) 45. In the placebo group, researchers recorded a 1.8 reduction in 
the mean number of migraine days (p<0.001) 45. For the second efficacy point researchers 
found that fifty percent of participants that received 140 mg erenumab and 43.3% of 
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patients in the 70 mg erenumab reported a fifty percent or more decrement in the mean 
number of monthly migraine days (p<0.001). This was a marked difference compared to 
26.6% of the participants that took placebo (p<0.001). Moreover, the results 
demonstrated a reduction in the number of days by 1.6 days in the participants that 
received 140 mg dose of erenumab and a reduction by 1.1 days in the participants that 
received 70 mg dose of erenumab, both which were higher than 0.2 days measured in 
participants that received placebo (p<0.001). Scores on the Migraine Physical Function 
Impact Diary were enhanced by 4.8 and 4.2 points in the 140 mg and 70 mg erenumab 
groups  respectively (p<0.001). The participants in the placebo group reported a 2.4 point 
improvement in the Impact Diary for study subjects that received placebo (p<0.001). 
Every day-activities scores were enhanced by 5.9 and 5.5 points in the 140 mg (p<0.001) 
and 70 mg erenumab groups (p<0.001) respectively. There was a 3.3 point improvement 
in the placebo group (p<0.001). The rates of adverse events were similar between study 
participants in the erenumab and placebo groups. Overall, erenumab resulted in 2 
additional headache days without headache per month when compared to placebo. 
Erenumab vs. Placebo ARISE Trial Efficacy 
Patients receiving erenumab experienced a change of 2.9 monthly migraine days, 
a 1.1 increase from the reported change of 1.8 days reported by study participants for the 
monthly migraine days in the participants that received placebo (p<0.001).46 29.5 % of 
participant in the placebo group in comparison to the 39.7% of patients in the erenumab 
group  experienced a greater than fifty percent reduction in mean monthly migraine days 
(p=0.010). The erenumab group displayed a greater reduction in the acute migraine 
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treatment by 1.2 days in the erenumab participant group versus 0.6 days in the participant 
group that took placebo. (p=0.0002) Migraine-specific medication treatment days were 
reduced by 1.2 days in the erenumab group compared to 0.6 days in the placebo group, 
with an overall difference of 0.6 days (p=0.0002).  A greater than five-point reduction 
rate in Migraine Physical Function Impact Diary-Everyday Activities was seen in 35.8% 
of participants in the placebo and 40.4% of patients in the erenumab groups respectively 
(p=0.26).  The most frequent adverse events reported were upper respiratory tract 
infection, injection site pain, and nasopharyngitis. Erenumab resulted in about 1 
additional headache free day per month compared to placebo. 
 Open Label Erenumab Study 
At the time of the 3 year analysis 34% of participants that took the 70 mg dose 
and 5.6% of participants that took the 140 mg erenumab group discontinued the trial. 
21% noted “patient request” as the reason for discontinuation, with only 3.1% mentioning 
lack of efficacy as reason for discontinuation.  The median exposure in both participants 
in the 140 mg or 70 mg group was 3.2 years.61 In this study, constipation was not a 
frequent side effect as the incident rate was 1.8 per 100 patient-years. The most frequent 
adverse events in greater than 4% of participants were sinusitis, back pain, influenza, and 
upper respiratory tract infection. The exposure-adjusted rates of severe adverse events 
were recorded as 4.2 years in this study. Researchers observed no increase in  
cardiovascular events in participants during this study. 
Botox vs. Placebo PREEMPT1 
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The PREEMPT1 trial did not meet statistical significance for their pre-designated 
primary endpoint, which was to assess for a mean change in monthly mean headache 
episode frequency between baseline and week 24 of the trial (p=0.344)48. Botox appeared 
safe and well tolerated, there were very few reactions when Botox was administered to 
participants. For the secondary endpoint of frequency of headache days there was a 7.8 
reduction in study participants taking Botox compared with participants taking placebo 
pills (p=0.006). Researchers also found that study participants taking Botox had a 
reduction in the frequency of migraine days by 7.6 days.  
Botox vs. Placebo PREEMPT2 
Botox was more effective than placebo for the primary end point, frequency of 
headache days per 28 day compared to baseline (p<0.001)49. Botox was favored in all 
secondary endpoint comparisons. Participants in the PREEMPT2 trial experienced a 
reduction by 9 days in comparison to placebo (p<0.001) for the primary endpoint. In 
PREEMPT2, participants experienced a decrease in the baseline frequency of migraine 
days by 8.7 days, a reduction of 8.3 days in the frequency of moderate/severe intensity  
headache days (p<0.001). There was a 4.9 change from baseline score in the HIT-6 
scores and a 5.3 change from baseline in the frequency of headache episodes. Botox was 
safe and well tolerated by participants in the study. There were very few patients (only 
3.5% in the Botox group and 1.4% in the placebo group) that discontinued the study due 
to adverse events.  
Botox vs. Placebo COMPEL 
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In the COMPEL study, participants experienced a reduction in headache days, 
with -9.2 days and -10.7 days at 60 weeks and 108 weeks respectively(p<0.0001).50 
Researchers observed a reduction from by 6.5 days at week 24 in the frequency of 
moderate or severe headache days recorded by participants (p<0.0001). Participants also 
demonstrated improved HIT-6 scores starting at the 12th week, and continuing up through 
week 108 of the study (p<0.0001). The HIT-6 score was decreased by 4.4 points from the 
participant’s baseline score until the end of the study (p<0.0001). The most common  
adverse events related to Botox treatment were neck pain (18.3% of participants), ptosis 
(0.4%), and rash (0.4%).  
Botox vs. Erenumab 
The number of monthly red days (impacted ability to function or need for triptan 
use), decreased by 6.4 days at 3 months (p=0.001), 6.5 days at 9 months (p=0.001), and 
6.8 days at 6 months (p=0.001).  When researchers assessed the number of headache-free 
(green) days, they reported that patients  had a 6.9 day improvement at 6 months, 5.7 day 
improvement at 3 months, and 7.4 day improvement at 9 months respectively. Moreover, 
patients continued to improve in the number of headache-free days patients.54 The most 
common side effect of erenumab use was constipation. Some limitations of this study 
include that it was non-placebo controlled, and as such was not possible to infer that the 
results of this study are due to causality, because of the additional potential confounding 
effect of attrition bias due to drop out rates and incomplete data at the time of analysis.54 
Table 3. Efficacy of Acute Treatment 
 Clinical Trial Freedom from pain at 
2 hours 
Placebo Number of 
Participants  
ACHIEVE I 37 
Ubrogepant vs. Placebo  
19.2% in 50 mg group 




ACHIEVE II 38 
Ubrogepant vs. Placebo  
20.7% in the 25 mg  
group 
21.8% in the 50 mg 
group 
14.3% 1465 
Rimegepant vs. Placebo 
40 
21% 11% 1800 
Sumatriptan vs. Placebo 
43 
50% in the 50 mg 
group 




Table 4. Efficacy of Preventative Treatment: erenumab by Trial 
Clinical Trial 50% reduction from 
baseline in the mean 
monthly migraine 
days 
Placebo Number of 
Participants 
LIBERTY45 30% 14% 246 
ARISE47 39.7% 29.5% 1147 
STRIVE 46 50% in the 140 mg 
group 




Table 5. Efficacy of Preventative Treatment: Botox PREMPT1  




baseline and week 24 
Placebo Number of 
Participants 
PREEMPT 148 No difference No difference 679 
 
Table 6. Efficacy of Preventative Treatment: Botox PREMPT2  
Clinical Trial Mean change of 
headache days per 28 
days from baseline 
Placebo Number of 
Participants 
PREEMPT 2 49 -9 -6.7  705 
 
Table 7. Efficacy of Preventative Treatment: Botox COMPEL  
Clinical Trial Headache day 
reductions at 108 
weeks 
Placebo Number of 
Participants 







There are currently no studies directly comparing rimegepant, ubrogepant, and 
sumatriptan for superiority in acute migraine treatment. Analyzing the results of the 
previous trials, sumatriptan, rimegepant, and ubrogepant have all been shown to be more 
efficacious than placebo in the acute treatment of episodic migraine; as such, we cannot 
establish superiority of one medication over another. Rather, this thesis analyzes the 
efficacy of sumatriptan, rimegepant, and ubrogepant in acute treatment based on the 
primary outcomes. The primary outcomes of the pivotal trials for ubrogepant and 
rimegepant were pain freedom at 2 hours post-dose, and freedom of most bothersome 
associated migraine symptom at 2 hours post-dose. 37,38,39,40 For these endpoints, both 
ubrogepant and rimegepant had comparable results, with the appearance of similar 
efficacy.37,38,39,40 In ACHIEVE I37, 38.6% of participants in the 50 mg ubrogepant group 
experienced pain freedom 2 hours post dose (p=0.002) and in ACHIEVE II38, 21.8% of 
participants also reported pain freedom at 2 hours in the 50 mg dose ubrogepant group . 
While both the 50 mg dose and 100 mg dose met the primary  endpoints, participants in 
the 100 mg dose reported more side effects than in the 50 mg dose.37 From this data, it 
could be beneficial to start patients with a 50 mg dose, and then titrate to 100 mg if 
patients are not experiencing migraine relief. In ACHIEVE II, MBS was reported by 
38.9% of individuals in the ubrogepant 50 mg dose group. Results for the 25 mg dose 
were not significant for MBS (P = 0.07). In the ACHIEVE I trial, the percentage of 
patients who reported freedom from the most bothersome symptom at 2 hours was 38.6% 
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in the 50 mg ubrogepant group (p=0.002). Rimegepant at a 75 mg dose was more 
effective than placebo for freedom from pain. The study reported 21% of individuals in 
the rimegepant group reported freedom from pain, but only 11% of individuals that took 
placebo reported freedom from pain (p<0.0001).40 35% of participants in the rimegepant 
group experienced freedom from the most bothersome symptom compared to 27% of 
participants given placebo (p=0.0009). 40Sumatriptan also proved to be more efficacious 
than placebo, but a disadvantage to sumatriptan is that sumatriptan is contraindicated in 
those with cardiovascular disease.43,44 Analyzing the safety factors, indications for use, 
and contraindications for rimegepant, ubrogepant, and sumatriptan, we can state that all 
three acute treatment options appear to be efficacious for acute treatment, with 
rimegepant and ubrogepant the superior option for individuals with, or at risk, for 
cardiovascular health conditions. Further active drug trials are needed to make a direct 
comparison between the doses of the medications. 
Preventative Treatment 
There are currently no studies directly comparing erenumab and Botox for 
superiority in preventative migraine treatment. Analyzing the results of the previous 
trials, erenumab and Botox have both been shown to be more efficacious than placebo in 
the preventative treatment of chronic migraine; as such, we cannot establish superiority 
of one medication over another.  Rather, this thesis compares the efficacy of these 




 In the LIBERTY trial, participants that were allocated to the erenumab group 
reported 9.2 days in the mean monthly number of migraine days were 9.2 and participants 
assigned to placebo reported 9.3. 45 Furthermore, at the 12th  week of the study, 30% of 
patients that received erenumab reported that they experienced a 50% or greater reduction 
in the monthly number of migraine days, which is 2 times more than participants 
allocated to the placebo group. The placebo group reported that 14% of the participants 
experiences a 50% or greater reduction in the monthly number of migraine days 
(p=0.002).45 In the STRIVE trial, by the fourth to sixth month, the number of migraine 
days per month were reduced from baseline by 3.2 in participants that received 70 mg 
erenumab group and by 3.7 days in the participants received 140 mg of erenumab,  and 
1.8 days in the participants that received placebo (p<0.001).45 The mean number of 
migraine days each month had at least a fifty percent reduction or more for less than half 
of the study participants (43.3%) that used the 70 mg erenumab medication and fifty 
percent of study participants in the 140 mg erenumab group. These percentages are 
double the efficacy experienced in the placebo group in which only 26.6% of study 
participants had a fifty percent reduction in headache days (p<0.001). In the ARISE trial 
patients receiving erenumab experienced a reduction of 2.9  monthly migraine days, 
compared with a 1.8 day reduction in monthly migraine days for placebo (p<0.001).46 
Additionally, 39.7 % of participants in the erenumab group experienced a greater than 
50% reduction in monthly migraine days compared to 29.5% of participants receiving 
placebo (p=0.010). 46  
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In the PREEMPT1 the results were not significant. This means that there was not 
a difference in the effectiveness of  between Botox and  placebo for decreasing headache 
episode frequency at week 24. (p=0.344)48. In this trial, Botox was not shown to reduce 
the number of headache episodes from the participants number of episodes at baseline. 
This is very interesting to note, but one should also be aware that the primary endpoints 
and secondary endpoints are different in PREEMPT2. Since researchers did not find a 
statistical difference in the first trial this may have been taken into consideration with 
PREEMPT2. The primary endpoint for this trial was to determine the average or mean 
change in the frequency of headache days at week 24 compared to the beginning of the 
study. 49 In PREEMPT 2, researchers found that Botox was effective at reducing the 
frequency of headache days by 9 days (p<0.001)49. When assessing Botox’s efficacy in a 
year long study (COMPEL), the frequency of headache days in study participants  were 
reduced by 6.5 days at week 24 compared to baseline (p<0.0001)50.  Only one patient in 
the COMPEL study reported a serious treatment-related adverse event (rash)50. The most 
frequent adverse events were nasopharyngitis, injection site pain, and back pain in the 
erenumab trials. Erenumab appears to be effective, safe, and well tolerated for the 
treatment of both episodic and chronic migraine based on the pivotal trial and long-term 
safety data we have thus far61. Botox is also effective, safe, and well tolerated in most 
patients for the prevention of chronic migraine. The most common side effect for 
participants in trials in which participants were treated with Botox were neck pain, ptosis, 
and rash.48,49,50 In the three mentioned erenumab trials: LIBERTY, ARISE, and STRIVE, 
participants that received erenumab showed  reductions in monthly  migraine days, and 
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decreased use of  migraine specific acute medications. Results for Botox therapy have 
been mixed. Botox treatment did not meet its primary endpoint in the PREEMPT 1 trial. 
Botox therapy decreased mean monthly headache days and days that a participant needed 
to use acute treatment to relieve a migraine of use in the COMPEL and PREEMPT 2 
trials. Erenumab is effective as a preventative medication, and appears that it can be 
effective in patients who have not had success with Botox treatments. Erenumab is 
advantageous as a medication for the treatment of migraine as it can be utilized to treat 
both episodic and chronic migraine. Erenumab is also advantageous in that it has the 
benefit of once monthly subcutaneous dosing at home, while Botox consists of 31 
injections in the head, neck, and shoulders once every 12 weeks.  
Limitations 
A limitation of this thesis is that it is retrospective. The inferences within this 
thesis are based on past data17 Another limitation is that when comparing these studies, 
there are differences in study design methodology, which can make direct comparisons 
difficult when interpreting the  efficacy between CGRP medications and conventional 
treatments such as sumatriptan and Botox. Additionally, there are no randomized control 
trials to date directly comparing the discussed preventative and acute migraine therapies, 
and only one of the mentioned trials in this analysis included an active drug comparator42. 
Study measures or the dependent variables also differed between studies. In Talbot’s 
2021 study54, level of disability and days with migraine pain were recorded based on a 
less rigid color system, while the clinical trials ARISE, STRIVE, and LIBERTY 45,46,47 
assessed efficacy by looking for an overall change in mean monthly migraine days. 
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Additionally, some of the gepant trials allowed the use of other migraine acute rescue 
medications if initial study drug was ineffective, while others did not. Rescue medication 
was allowed in the Marcus et al. 2014 study42, but was not utilized in the ubrogepant 
studies34,35. Instead, participants were asked to take another dose of study medication 
(either ubrogepant or placebo) if their pain was not relieved from the first allocated study 
dose. The ACHIEVE  I and II  trials were the only studies that involved a satisfaction 
questionnaire which may be a more subjective measure as levels of satisfaction can differ 
from patient to patient. One can only extrapolate that with relief of symptoms a 
participant would become more satisfied.  
Another example of limitations in these studies is sample size. In the Marcus, et 
al. 2014 study42, a 75mg dose of rimegepant  relieved pain at 2 hours post dose in 31.4% 
of participants, but in the study by Lipton et. al41 rimegepant led to pain freedom 2 hours 
post dose in only 19.6% of participants. This discrepancy in percentage of patients with 
pain freedom may have been secondary to the large difference in sample size (over 1300 
participants in the Lipton et al.41 compared to 91 participants in the Marcus et al. study42).  
In order to better assess acute treatment efficacy and safety, it would be beneficial to have 
future randomized control trials where participants treat multiple migraine attacks with 
the study drugs, in addition to the previously performed single attack treatment trials for 
rimegepant, ubrogepant37,38 and sumatriptan43,44.  For treatment prevention, the 
LIBERTY, ARISE, and STRIVE trials45,46,47, were very thorough, but would have 
benefited from longer study duration as well to assess longer-term efficacy and safety. 
Future studies in both acute and preventative treatment would also benefit from being 
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more ethnically diverse, as most randomized control trials to date on migraine prevention 
and acute treatment are limited to mainly white, non-Hispanic or Latino populations. It is 
important to determine how  medications may affect people of various ethnicities, such as 
African American, Latino, and Asian Americans. Furthermore, recruiting more patients 
for studies with different BMIs can also provide further support for efficacy.  
Recommendations 
CGRP mAbs 
There are several advantages to CGRP mAbs: a) patients may be more likely to 
adhere to and tolerate CGRP mAbs than any other treatment options,17 b) they do not 
interact with other medications or produce toxicity in the liver, 17  c) their long half-lives 
of 20 to 30 days allow for once monthly dosing, 51  d) they have a high affinity and 
specificity for the CGRP receptor or CGRP molecule, which can decrease unwanted off 
target effects.51 There have been no reports to date of any significant adverse 
cardiovascular events secondary to use of the CGRP mAbs. 51, other than erenumab 
leading to possible elevations in blood pressure in some participants post-dose. 62 
Cardiovascular disease or history of stroke has been a contraindication to other previous 
migraine treatments, such as triptans. A disadvantage of the CGRP mAbs is that they can 
cause injection site reactions, and due to the presence of latex in the cap, erenumab is 
contraindicated for use in individuals with a latex allergy. 51 Botox therapy is given once 
every 12 weeks. 17 The most common adverse effects experienced while taking Botox are 
neck pain, facial muscle weakness, and eyelid ptosis.  Similar to the CGRP mAbs, Botox 
also has a low potential to generate an immune response in patients taking this 
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preventative medication. 53. Erenumab appears to be an effective and a wonderful 
alternative for those who have not experienced success with Botox treatments and other 
preventative medications. In comparison to Botox that is given in a clinic and must be 
administered by a healthcare professional, erenumab can be administered by the patient 
in the convenience of their own home. 
CGRP receptor antagonists 
When assessing treatment options in the acute treatment of migraine, rimegepant 
and ubrogepant appear to have comparable efficacy to sumatriptan. Within this class of 
migraine medications, the patient may find rimegepant very attractive as it dissolves in 
the mouth and can be taken without water, versus ubrogepant which is taken as an oral 
pill that one must swallow. 
Cost 
The annual list price is $4,89655 for 10 pills of Ubrogepant per month and 8 pills 
of Rimegepant per month respectively; the annual list price for erenumab is $6,900. 56 
CGRP inhibitors reduce the number of migraine days which decreases the migraine-day 
related costs by $8,482 over ten years compared to supportive care.57 Therefore, we can 
infer that CGRP inhibitors will save patients money in the long run. In terms of 
accessibility, patients on commercial insurance plans may have an easier time acquiring 
CGRP inhibitors. At this time, all insurance plans require patients to try a certain number 
of other preventative or acute medications prior to approving coverage. For example, 
insurance companies may require that a patient first tries and fails to improve on at least 
one anti-hypertensive, anti-epileptic, anti-depressant and Botox before qualifying to try a 
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CGRP mAbs for migraine prevention. In addition, insurance companies may require that 
the medication is prescribed by, or that the patient has been diagnosed with migraine by a 
neurologist, which may not be feasible for patients that live in rural or low access areas.  
CGRP Inhibitors Safety 
Aspartate Transaminase (AST) and Alanine Transaminase (ALT) are measures 
that can be used to assess for liver toxicity or drug metabolism. Bilirubin processing is 
another measure that can be used to determine metabolism and assess liver function. 
Abnormal values of AST, ALT and bilirubin can indicate liver damage. In the 
randomized control trials for the gepants liver toxicity was not noted, as the ALT and 
AST levels were not more than 3 times the normal limit and bilirubin processing did not 
exceed normal range. 37,38,39,40 Erenumab is a 100% humanized monoclonal antibody 
treatment. CGRP gepants37,38,39,40 and CGRP mAbs45,46,47 appear to be well tolerated 
overall with few adverse effects. The most common side effects with CGRP gepants are 
nausea, dizziness, or dry mouth,37,38,39,40 and the most common side effect with CGRP 
mAbs are injection site reactions and constipation with erenumab. 45,46,47 Significant 
cardiovascular or cerebrovascular events have not been seen with the CGRP mAbs or the 
gepants. Therefore, CGRP inhibitors appear to be a safer option than medications that 
have vasoconstrictive properties such as the triptans, in individuals with multiple vascular 
risk factors, or a history of vascular disease.37,38,39,40   
Conclusion & Future Directions 
Based on the analysis of the comparative and pivotal trials for the CGRP 
inhibitors, gepants (ubrogepant and rimegepant) and erenumab appear to be just as 
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effective as conventional treatments such as sumatriptan for acute treatment and Botox 
for migraine prevention.  Ubrogepant and rimegepant are the only FDA approved gepants 
in the United States for the acute treatment of migraine. Telcagepant development was 
stopped due to concerns for liver toxicity and atogepant is a currently undergoing clinical 
trials for migraine prevention, and has not yet been FDA approved58. Sumatriptan was 
chosen as a comparator to ubrogepant and rimegepant, as it is the most commonly 
prescribed triptan in the United States for migraine acute treatment.  In the future, the 
CGRP medications can be compared to other medications used to treat migraines. In the 
future, more direct drug comparator studies are needed to determine how CGRP 
medications compare to other migraine treatment medications such as triptans or Botox. 
Many pharmaceutical companies do not conduct trials in which migraine medications are 
compared to each other, most likely due to economic reasons. There are some open label 
studies that compare medications to each other but the outcome measures may be more 
subjective than outcome measures in clinical trials.  
Another future direction that could provide insightful data is comparing the 
gepants to another new abortive migraine medication, lasmiditan, which is an agonist at 
the serotonin receptor 5-HT 1F. Furthermore, CGRP mAbs could be compared with other 
preventative medications such as propranolol or topiramate.  It would also be beneficial 
for future research to assess the efficacy of the CGRP inhibitors in the treatment of other 
primary headache disorders such as new daily persistent headache, or secondary 
headache disorders due to medication overuse.  
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Ultimately, there is not a one-size-fits-all option when it comes to migraine 
treatment. In the end, a migraine therapy may or may not work for an individual due to a 
variety of factors. It is therefore best to analyze all options, and work with the individual 
to determine which migraine treatment is best for them. Cost and insurance coverage may 
be a limiting factor for certain medications. The CGRP mAbs may be a good option for 
individuals that have failed a number of medications for migraine prevention in the past, 
have difficulty adhering to daily medication regimens, who have multiple medical co-
morbidities putting them at high risk for drug interactions, or in whom vasoconstrictive 
medications are contraindicated. Similarly, the gepants for acute migraine treatment are 
an attractive option for patients in whom vasoconstrictive options, such as traditional 
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